A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.
The Motley Fool on MSN7d
Down 93%, Is It Finally Time to Buy Moderna?In addition to its COVID-19 vaccine, Moderna markets an RSV vaccine that earned approval in 2023. Pfizer has more resources ...
Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...
Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...
RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...
A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...
Risk factors for RSV transmission included index case viral detection 1 week or more after an index case and a household contact age of 12 years or younger. Of 120 sequenced specimens, the main ...
Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...
From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback